

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A01/2018 WB

DESPATCHED ON 20TH MARCH 2018

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A3; B7, B60; Cw3, Cw7; DR4, DR15; DQ6, DQ8

					Summary of Results												
					PBL				T-Cells				B-Cells				
					8	8	8	8	31	30	30	31	28	28	29	29	
					1	0	0	0	1	0	0	0	4	2	4	0	
					7	8	8	8	30	30	30	31	24	26	25	29	
					0	0	0	0	0	1	1	0	5	5	4	4	
					12.5%	0.0%	0.0%	0.0%	3.2%	0.0%	0.0%	0.0%	14.3%	7.1%	13.8%	0.0%	
					87.5%	100.0%	100.0%	100.0%	96.8%	100.0%	100.0%	100.0%	85.7%	92.9%	86.2%	100.0%	
Consensus					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
HLA Antibody Specificity (Defined By CDC)					A3	B14+	DR1	B8 DR3	A3	B14+	DR1	B8 DR3	A3	B14+	DR1	B8 DR3	
					Without DTT				Without DTT				Without DTT				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment		Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
9	YES	YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	Low B-cell viability
11	YES	YES	YES		Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
12	YES	YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
20	YES		YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
23		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
24		YES	YES						Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
25		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
28		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
34		YES	YES						Negative	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
38	YES	YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
39		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
41		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
42	YES		YES		Negative	Negative	Negative	Negative					Negative	Negative	Positive	Negative	
45		YES	YES						Negative	Negative	Negative	Negative	NT	NT	Negative	Negative	Low viability of B-cells and inconsistency in results for sera 1 and 2.
51		YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
54		YES	YES						Negative	Negative	Negative	Negative	NT	NT	NT	NT	The B-cell yield and viability unacceptable to report valis XM results
58		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Low B-cell viability
101		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
114		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
116		YES	YES						Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
117	YES				Negative	Negative	Negative	Negative					Negative	Negative	Negative	Negative	
136		YES							Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Low viability of B-cells.
145		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
149	YES				Negative	Negative	Negative	Negative									
162		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
181		YES	YES						Negative	Negative	Negative	Negative	NT	Negative	Negative	Negative	
186		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
204		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
206		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
223		YES	YES						Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
227		YES	YES						Negative	NT	NT	Negative	Negative	NT	NT	Negative	Technical failure
268		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
284		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
311		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
315		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A01/2018 WB

DESPATCHED ON 20TH MARCH 2018

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	0	0	0	0	0	0	0	0	0	0	0	0	80%	80%	80%
11	4	-	-	-	-	-	-	-	6	-	-	-	90%	95%	75%
12	-	-	-	-	-	-	-	-	40%	20%	-	-	95%	95%	85%
20	1	1	1	1					1	1	1	1	95%		95%
23					1	1	1	1	1	1	1	1		90%	90%
24					30%	10%	10%	10%	40%	10%	10%	10%		90%	90%
25					1	1	1	1	1	1	1	1		99%	99%
28					1	1	1	1	1	1	1	1		95%	85%
34					1	1	1	1	2	4	4	1		90%	90%
38	1	1	1	1	1	1	1	1	1	1	1	1	95%	100%	85%
39					-	-	-	-	-	-	4	-		98%	98%
41					10	10	10	10	20	15	60	10		90%	90%
42	<10%	<10%	<10%	<10%					<10%	<10%	40-60%	<10%	95%		95%
45					1	1	1	1	NT	NT	1	1		99%	80%
51					0	0	0	0	0	0	0	0	90%	90%	90%
54					5%	5%	5%	5%	NT	NT	NT	NT		95%	50%
58					5	5	5	5	20	20	20	20		95%	20%
101					1	1	1	1	1	1	1	1			
114					1	1	1	1	2	2	2	2			
116					1	1	1	1	0	0	0	0		85%	45%
117	1	1	1	1									90%		
136					1	1	1	1	1	1	1	1		95%	95%
145					-	-	-	-	-	-	-	-		100%	80%
149	-	-	-	-									85%		
162					1	1	1	1	1	1	1	1		85%	45%
181					1	1	1	1	1	1	2	1		100%	100%
186					0	0	0	0	0	0	0	0		99%	99%
204					1	1	1	2	2	2	2	2		90%	80%
206					0	0	0	0	0	0	0	0		100%	100%
223					2	1	1	1	-	-	-	-		95%	70%
227					-	-	-	-	-	-	-	-		98%	98%
268					1	1	1	1	1	1	1	1		90%	90%
284					1	1	1	1	1	1	1	1		99%	85%
311					-	-	-	-	-	-	-	-		95%	95%
315					1	1	1	1	1	1	1	1			

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A01/2018

DESPATCHED ON 20TH MARCH 2018

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A3; B7, B60; Cw3, Cw7; DR4, DR15; DQ6, DQ8

				Summary of Results												
				PBL				T-Cells				B-Cells				
Total tested	7	7	7	7	28	27	27	28	25	25	26	26				
Positive	1	0	0	0	1	0	0	0	3	1	6	0				
Negative	6	7	7	7	27	27	27	28	22	24	20	26				
NT	0	0	0	0	0	1	1	0	5	5	4	4				
% Positive	14.3%	0.0%	0.0%	0.0%	3.6%	0.0%	0.0%	0.0%	12.0%	4.0%	23.1%	0.0%				
% Negative	85.7%	100.0%	100.0%	100.0%	96.4%	100.0%	100.0%	100.0%	88.0%	96.0%	76.9%	100.0%				
Consensus	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative				
HLA Antibody Specificity (Defined By CDC)	A3	B14+	DR1	B8 DR3	A3	B14+	DR1	B8 DR3	A3	B14+	DR1	B8 DR3				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	With DTT				With DTT				With DTT				Comments
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	
11	YES	YES	YES	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
12	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
15		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
20	YES		YES	Negative	Negative	Negative	Negative					Negative	Negative	Negative	Negative	
24		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
25		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
28		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
34		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
38	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
39		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
41		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
42	YES		YES	Negative	Negative	Negative	Negative					Negative	Negative	Positive	Negative	
45		YES	YES					Negative	Negative	Negative	Negative	NT	NT	Negative	Negative	
51		YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
54		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	
58		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	
101		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
114		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
116		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	
149	YES			Negative	Negative	Negative	Negative									
162		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
181		YES	YES					Negative	Negative	Negative	Negative	NT	Negative	Negative	Negative	
186		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
204		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
206		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
227		YES	YES					Negative	NT	NT	Negative	Negative	NT	NT	Negative	
268		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
284		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
311		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
315		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A01/2018

DESPATCHED ON 20TH MARCH 2018

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	0	0	0	0	0	0	0	0	0	0	0	0	80%	80%	80%
11	2	-	-	-	-	-	-	-	6	-	-	-	90%	95%	75%
12	-	-	-	-	-	-	-	-	-	-	-	-	95%	95%	85%
15					0	0	0	0	0	0	1	0		99%	99%
20	1	1	1	1					1	1	1	1	95%		95%
24					30%	10%	10%	10%	50%	30%	30%	20%		90%	90%
25					1	1	1	1	1	1	1	1		99%	99%
28					-	-	-	-	1	1	1	1		95%	85%
34					1	1	1	1	2	2	2	1		90%	90%
38	1	1	1	1	1	1	1	1	1	1	6	1	95%	100%	85%
39					-	-	-	-	-	-	6	-		98%	98%
41					10	10	10	10	20	10	80	10		90%	90%
42	<10%	<10%	<10%	<10%					<10%	<10%	20-40%	<10%	95%		95%
45					1	1	1	1	NT	NT	1	1		99%	80%
51	0	0	0	0	0	0	0	0	0	0	0	0	90%	90%	90%
54					5%	5%	5%	5%	NT	NT	NT	NT		95%	50%
58					5	5	5	5	-	-	-	-		95%	20%
101					1	1	1	1	1	1	1	1			
114					1	1	1	1	2	1	2	2			
116					1	1	1	1	0	0	0	0		85%	45%
149	-	-	-	-									85%		
162					1	1	1	1	1	1	1	1		100%	100%
181					1	1	1	1	-	1	1	2		100%	100%
186					0	0	0	0	0	0	0	0		99%	99%
204					2	2	2	2	2	2	2	4		90%	80%
206					0	0	0	0	0	0	0	0		100%	100%
227					-	-	-	-	-	-	-	-		98%	98%
268					1	1	1	1	1	1	1	1		90%	90%
284					1	1	1	1	1	1	1	1		99%	85%
311					-	-	-	-	-	-	-	-		95%	95%
315					1	1	1	1	1	1	1	1			